Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.
The firm said that in its product pipeline in 2019 it focused on organ transplant and lung health, involving use of its multiplexed research-use TORdx Lung tests.
The firm also said it is contemplating selling its therapeutics division, and appointed David Bench as its new CFO.
The German company reported its quarterly earnings for the first time as a public company, following the completion of its IPO on Nov. 7.
Yourgene said it continues to consider additional acquisition opportunities to enhance its earnings and to acquire complementary technologies.
The firm's diagnostics and genomics group saw a 5 percent year-over-year revenue increase in the fourth quarter.
The company also said that it expects a clearance decision from US regulators in the near term on a lower respiratory tract infection test that runs on its Unyvero system.
The firm attributed the decline to reluctance of US customers to buy additional units of its Epi proColon colon cancer test amid reimbursement uncertainty.
The company incurred a net loss of $5.2 million, or $.10 per share, slightly exceeding the $.09 per share loss that analysts had predicted on average.
The company signed a distribution agreement in Japan for its Idylla products and also initiated a listing of €150 million in unsecured convertible bonds.